All rights reserved. No reuse allowed without permission.

1 Genetic Markers and Predictive Factors Influencing the Aggressive

2 Behavior of Cerebral Cavernous Malformation

- 3 Gustavo F. Galvão M.D, PhD, Luisa M. Trefilio, Andreza L. Salvio P.h.D, Elielson
- 4 V. da Silva M.S.c, Soniza V. Alves-Leon M.D, P.h.D, Fabrícia L. Fontes-Dantas
- 5 Pharm.D, P.h.D, Jorge M. de Souza M.D, PhD.
- 6

7 ABSTRACT

8 Biological behavior of Cerebral Cavernous Malformation (CCM) is still controversial without clear-cut signature for biological mechanistic explanation of 9 lesion aggressiveness. There is plenty evidence implicating dysregulated 10 inflammatory and immune responses in vascular malformation pathogenesis, 11 including CCM. In the present study, we evaluated the predictive capacity of the 12 SNPs VDR^{rs7975232}, VDR^{rs731236}, VDR^{rs11568820} as well as expanded the analysis of 13 PTPN2rs72872125 and FCGR2Ars1801274 in relation to the aggressive behavior of 14 CCM and its implications in biological processes. This was a single-site 15 prospective observational cohort study with 103 patients enrolled, 42 had close 16 follow-up visits for a period of 4 years, focused on 2 main aspects of the disease: 17 (1) symptomatic event that composed both intracranial bleeding or epilepsy and 18 (2) precocity of symptoms. We report a novel observation that the PTPN2rs72872125 19 CT and the VDR^{rs7975232} CC genotype were independently associated with an 20 asymptomatic phenotype. Additionally, *PTPN2*^{rs72872125} CC genotype and serum 21 level of GM-CSF could predict a diagnostic association with symptomatic 22 phenotype in CCM patients, while the FCGR2Ars1801274 GG genotype could 23 predict a symptomatic event during follow-up. The study also found a correlation 24 between VDR^{Is731236} AA and VDR^{Is11568820} CC genotype to the time to first 25 symptomatic event. In summary, this study provides valuable insights into the 26 genetic markers that could potentially impact the development and advancement 27 of CCM. 28

29

KEYWORDS: Cerebral Cavernous Malformation, Diagnostic Biomarker,
 Prognostic Biomarker, *FCGR2A*, *PTPN2*, *VDR*

32 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 INTRODUCTION

Cerebral cavernous malformation (CCM) are vascular malformations 36 37 consisting of capillary-like channels with a single layer of endothelium and no intervening nervous tissue^{1,2}. CCM are among the most common vascular 38 malformation of the central nervous system (CNS) affecting 0.5%-1% of the 39 population, with magnetic resonance image (MRI) as the gold standard for the 40 diagnosis and the lesions evaluation should include the hemosiderin-sensitive 41 techniques as the susceptibility-weighted imaging (SWI)^{3,4}. Intracerebral 42 43 hemorrhage (ICH) and seizure, are the main clinical manifestations, followed by neurological disability without evidence of bleeding. However, many patients 44 45 remain asymptomatic throughout their life and it is not known what factors may predict aggressive manifestations in individual cases^{4,5}. 46

47 Usually, single cavernomas are detected in patients affected by sporadic forms and often associated with a developmental venous anomaly. Familial CCM 48 49 is mostly associated with the occurrence of multiple lesions that might increase in number and size with aging ⁶. The familial form of the disease is linked to 50 specific genes, (CCM1/KRIT1, CCM2/MGC4607 51 mutations on and CCM3/PDCD10), which encode distinct proteins involved in the endothelial cell 52 junction function and in the interaction with cytoskeletal proteins. The most 53 frequent and well-studied of the CCM genes is the CCM1/KRIT1, with mutational 54 analyses showing a Hispanic-American ancestral haplotype^{7,8}. CCMs are 55 characterized by an incomplete disease penetrance, being 80% to the CCM1 56 form, near 100% to the CCM2 and 60% to the CCM3 form^{9,10}. Furthermore, the 57 58 discovery of *PIK3CA* mutations in CCM lesions provides important new insights into the genetic factors that contribute to the variable expression and progression 59 60 of the disease phenotype ¹¹.

Biological behavior of CCM is still controversial without clear-cut signature for biological mechanistic explanation of lesion aggressiveness. There is plenty evidence implicating dysregulated inflammatory and immune responses in vascular malformation pathogenesis, including CCM. Several dysregulated pathways have been confirmed in the transcriptome of CCM lesions, which are out of balance having an impact on the permeability of the blood-brain barrier and the stability of endothelial tight junctions ¹². Notably, inflammatory and immune

cells such as monocytes, macrophages, B and T cells, are present in human
CCM lesions as well as in mouse models of CCM^{13–17}. Recently, our group have
demonstrated an adaptive immune-cellular reaction to CCM within CD20+ and
CD68+ in the pericavernous tissue of an aggressive pharmaco-resistant epilepsy
patient¹⁸. Moreover, the severity of the disease has been linked to genetic
polymorphisms within inflammatory and immune response genes ¹⁹.

The significance of certain genetic variants in the development of CCM has 74 been established, underscoring the need for further investigation into their 75 76 specific roles. Tang et al 2017 showed allele T for SNP in *TLR4* (rs10759930) gene is associated with increased CCM lesion number ²⁰. Some studies have 77 78 also identified genetic polymorphisms in genes related to oxidative stress with a significant impact on inter-individual variability in CCM disease onset and severity 79 ²¹. Of particular interest, in a previous study, our group demonstrated the 80 association of FCGR2Ars1801274 GG and PTPN2rs72872125 CT genotype with a 81 symptomatic profile of CCM patients in a smaller cohort ²². 82

In the present study, we evaluated the predictive capacity of the SNPs 83 VDR^{rs7975232}, VDR^{rs731236}, VDR^{rs11568820} as well as expanded the analysis of 84 PTPN2rs72872125 and FCGR2Ars1801274 in relation to the aggressive behavior of 85 CCM and its implications in biological processes. We also looked for plasmatic 86 inflammatory cytokines expressed in the patients, verifying a pattern of 87 heterogeneity of plasmatic expression and any correlation with the genetic 88 variation identified with different clinical phenotypes of CCM. Using a multi-step 89 Bayesian approach, we thought to build a biomarker that could predict a 90 91 diagnostic and a prognostic aggressive phenotype of CCM.

92

93 METHODS

94 Study Design and Population

This was a single-site prospective observational cohort study. Qualified
researcher on human subjects conducted this study having been approved by
the National Council for Ethics in Research (CAAE 69409617.9.0000.5258).
Blood samples were collected between October 2017 to March 2023 and
informed consent was obtained. Strobe criteria were used to report the findings
of this study ⁶³.

The epidemiological data were defined at each clinical assessment. Patients were stratified as multiform when they harbor multiples CCM on SWI or Gecho or as isolated form when they had a single lesion at the CNS. Both definitions were based on MRI study with SWI or Gecho and the absence of venous development anomalies in the multiple cases in proximity.

106 CCM clinical presentation were identified as symptomatic (hemorrhage or 107 seizure) and asymptomatic. Intracerebral hemorrhage was defined based on the 108 consensus of Cavernous Angiomas with Symptomatic Hemorrhage (CASH) ⁵⁰. 109 The solely epileptic patients were defined as not having achieved previous 110 hemorrhagic consensus and whom the MRI evaluation depicted no hint of 111 hemosiderin beyond the usual smooth and regular deposit around a CCM lesion.

In this study, we focused in 2 mains aspects of the disease: (1) symptomatic 112 113 event that composed both intracranial bleeding or epilepsy and (2) precocity of symptoms. We considered that these presentations may reflect an aggressive 114 115 phenotype of the disease. We also designed six sub-group analysis in order to check for correlation - 60 years or older, female, familiar form, pure epileptic 116 without signs of lesion bleeding, pure symptomatic bleeding and infratentorial 117 lesion. Among the 103 consecutive cases, 42 had closely follow-up visit for a 118 period of 4 years. The remaining patients either did not have a clinical follow-up 119 visit or underwent surgical resection. 120

121

122 Sample collection and processing

Blood samples were collected with EDTA and processed by centrifugation at 720 123 x q and 4 °C for 5 min to separate the plasma. The plasma supernatants were 124 immediately stored at -80°C until further processing. The Genomic DNA (gDNA) 125 extraction was performed using the PureLink Genomic DNA Mini Kit according to 126 the manufacturer's recommendations (ThermoFisher Scientific, Waltham, 127 Massachusetts, USA). The quality of gDNA was determined by NanoDrop 2000 128 (ThermoFisher Scientific) followed by quantification using the Qubit dsDNA HS 129 Assay Kit (ThermoFisher Scientific) and Qubit Fluorometer3.0 (Thermo Fisher 130 Scientific). 131

132

133 Plasma isolation and Inflammatory Modulators Assessment

Proinflammatory cytokine and chemokine levels in plasma were measured using 134 a multiparametric immunoassay based on XMap-labeled magnetic microbeads 135 (Luminex Corp – Austin, TX, USA). A human ProcartaPlex [™] Panel (Invitrogen 136 - Waltham, MA, USA) was used to analyze a set of 18 cytokines and chemokines 137 (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-18, IL-21, IL-138 22, IL-23, IL-27, GMCSF and INF-y). The samples were measured according to 139 the manufacturer's instructions and simultaneously to avoid potential batch, as 140 described previously, using a BioPlex MAGPIX system (Biorad -Hercules, CA, 141 USA) ^{64,65}. Cyto/chemokine expression was measured in duplicate, and the levels 142 of inflammatory modulators were analyzed using Xponent v. 3.0 software 143 144 (Luminexcorp) and expressed in pg/ml.

145

Analysis of polymorphism of PTPN2^{rs72872125}, VDR^{rs7975232}, VDR^{rs731236}, VDR^{rs11568820} and FCGR2A^{rs1801274} genes

The SNPs investigated in this study are detailed in Table 1. The SNPs were 148 genotyped by allelic discrimination performed in QuantStudio[™] 3 Real-Time PCR 149 System (ThermoFisher) using TaqMan SNP genotyping assays (ThermoFisher). 150 The characteristics of the PTPN2^{rs72872125}, VDR^{rs7975232}, VDR^{rs731236}, VDR^{rs11568820} 151 and FCGR2A^{rs1801274} genes were obtained from the SNP bank of the National 152 Center of Biotechnology Information - NCBI (http://www.ncbi.nlm.nih.gov/). The 153 probes for each SNP were produced by Applied Biosystems ™ rs72872125 154 155 (C___98019281_10), rs7975232 (C_28977635_10), rs731236 (C 2404008 10), (C 2880808 10) 156 rs11568820 and rs1801274 (9077561_20). As the assay was designed and standardized to work with the 157 same thermal cycles, a single protocol was applied for both genes. Briefly, PCR 158 159 was performed with a 25 uL reaction mixture containing 10 ng DNA, TagMan® _Universal PCR Master Mix (1X), Probe TaqMan® _Gene Expression Assay 160 (1X), and DNAse free water for the final volume. The Real Time PCR conditions 161 were: initially 60°C for 30 seconds and then 95°C for 10 min, and subsequently 162 40 cycles of amplification (95 °C for 15 seconds and 60°C for 1 min), and then 163 60°C for 30 seconds. The five selected SNPs were amplified on separate plates. 164

In silico Structural Prediction of FCGR2A^{rs1801274} Protein and Phylogenetic Analysis

Since the *FCGR2A*^{rs1801274} SNP is the only with amino acid change, we performed a structural analysis using bioinformatic tools. *FCGR2A*^{rs1801274} transcript structure was predict by directly modifications of the wild-type *FCGR2A* using FASTA sequence obtained on NCBI database ⁶⁶. The new FASTA file was submitted to the Chimera software (developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311) for overall structural analysis ⁶⁷.

The evolutionary history was inferred using the MEGA-X software using the maximum likelihood method and Jones-Taylor-Thornton (JTT) matrix-based model. We first gathered the *FCGR2A* wild-type sequence from Homo sapiens and 19 other mammals to study the evolutionary conservation of this protein. Structural alignment was performed using the muscle algorithm that allows multiple sequencing alignment with high accuracy and high throughput ⁶⁸.

181

182 Statistical Analysis

Statistical analyses were performed with STATA 13 (StataCorp LP, TX, USA) and GraphPad Prism 9.0.0 MacOS (GraphPad Software, San Diego, California USA, <u>www.graphpad.com</u>). Categorical variables were expressed as n (%) and continuous data were given as mean and standard deviation (SD). A 2-tailed 2sample t test or Mann-Whitney test was applied for continuous variables while the association between two categorical variables was measured by Pearson Chi-square (χ 2) test when appropriate.

Allelic and genotypic frequencies were calculated for patient and control subjects 190 via direct gene counting. Genotypic distributions in Hardy–Weinberg equilibrium 191 (HWE) were evaluated by two-tailed x2-test. Linkage disequilibrium (LD) were 192 193 analyzed using: Linkage Disequilibrium Calculator (https://grch37.ensembl.org/Homo_sapiens/Tools/LD), 194 LDlink on https://ldlink.nih.gov/ Heatmap 195 and was plotted by https://www.bioinformatics.com.cn/en.The degree of LD between SNPs is 196 represented by R² and D[']. 197

Genetic polymorphisms were evaluated through a univariate and multivariable binary logistic regression adjusting for sex, age and familiar form when adequate in matter of phenotype (symptomatic and asymptomatic). Plasma cytokines were also evaluated between genotypes and phenotypes (symptomatic and asymptomatic). Values over 2 times de standard deviation were excluded from analysis due to possible bias results.

Genetic polymorphism and plasma cytokines verified as statistically different 204 between groups (both diagnostic and prognostic) were combined through a 205 206 canonical discriminant function analysis in order to build a biomarker-model of symptomatic profile. All the possible combinations showing significant 207 208 association in symptomatic individuals were build. Receiver Operating Characteristic (ROC) curves were generated along with a computed area under 209 the curve (AUC) for each combination individually and ROC curves were 210 211 compared to identify if any of them were statically superior then the others. The best model-biomarker to differentiate symptomatic and asymptomatic patients in 212 both diagnostic and prognostic scenario was selected according to the Akaike 213 214 Information Criteria (AIC), representing the best fit parsimonious model to the data with the fewest number of predictors. The optimal cutoff point was generated 215 from ROC curves utilizing the Youden index method. Mann-Whitney test was 216 217 then used to verify the difference in values generated using the modeled equation among symptomatic and asymptomatic patients and a logistic regression was 218 used to control for age and sex. A p value <0.05 was considered significant. 219

To balance baseline covariates between patients with and without symptoms during follow-up we used a propensity score matching (PSM) strategy. The strategy involved 1:1 pairing and nearest-neighbor methods. After PSM, the distribution of gender, familial form, and age was balanced between the groups and the biomarker analysis was remade.

Finally, A Kaplan-Meyer survivor analysis was carried out among patients who presented different polymorphism combinations. Hazard ratios were calculated with 95% confidence intervals through a log-rank test. Failure events were determined according to if there had been symptomatic presentation at some point in the patient's lifetime

231 Results

232 **Demographic and CCM lesions characteristics**

Out of 103 CCM patients enrolled in the study, 44 are multifocal/familial CCMs, 233 70 patients presented with symptomatic phenotype, which 48 presented a 234 235 symptomatic hemorrhage secondary to their CCM, and 22 presented with seizures and no history or signs of CCM bleeding on MRI. The median age of 236 enrolment was 45.6, within a mean age of 41.6 in the symptomatic group and 237 53.7 in epileptic sub-group. There were no significant differences in terms of sex, 238 age and form (sporadic vs familiar/multifocal) between the outcome groups 239 (Table 2). 240

241

242 Association of PTPN2^{rs72872125} and VDR^{rs7975232} to a Symptomatic Phenotype

243 and Plasmatic Cytokine Levels

The distribution of the genotypic frequencies of the PTPN2rs72872125, 244 VDR^{rs7975232}, VDR^{rs731236}, VDR^{rs11568820} and FCGR2A^{rs1801274} in symptomatic and 245 246 asymptomatic patients are shown in Table 3. All genotypic distributions were in Hardy-Weinberg equilibrium. Haplotype analysis indicated linkage disequilibrium 247 between VDR^{rs7975232} and VDR^{rs731236} (D'>0.99), corroborating what has already 248 been found in other populations (Figure 1A and Supplementary material). While 249 the other combinations segregate independently VDR^{rs11568820} and VDR^{rs731236} 250 (D'>0.04), VDR^{rs11568820} and VDR ^{rs7975232} (D'>0.317) (Figure 1A and 251 Supplementary material). A higher frequency of the PTPN2^{rs72872125} CT genotype 252 (OR 0.34, 95% CI 0.11-0.99, p = 0.04) and the VDR^{rs7975232} CC genotype (OR 253 254 0.06, 95% CI 0.006-0.612, p = 0.017) was observed in asymptomatic phenotype 255 in the age, familiar and female adjusted multivariable analysis, when compared with symptomatic patients (Table 3). The ROC analysis (Figure 1B) revealed that 256 patients with *PTPN2*^{rs72872125} CT genotype had a modest Area Under de Curve 257 (AUC 0.420, SE 0.05 CI 95% 0.334-0.506) and VDRrs7975232 CC individuals 258 (Figure 1C) had a pour accuracy (AUC 0.439, SE 0.03 CI 95% 0.370-0.508). 259

We also hypothesized that these genetic variants might influence the plasmatic inflammation signature of the CCM patients. We found that patients who harbor the *PTPN2*^{rs72872125} CT genotype showed a higher plasma level of IL-10 (p = 0.0146) (Figure 1D) and low levels of IL-18 (p = 0.0450) (Figure 1E) and

IFN-γ (p = 0.0310) (Figure 1F), while individuals with *VDR*^{rs7975232} at least one C allele had low plasma levels of IL-27 (p = 0.0055) and IL-23 (p = 0.0034) (Figure 1G-H). For other SNPs no significant difference in the levels of immune markers was observed. We did not observe any significant differences in the levels of these plasma molecules in relation to patient sex and form (sporadic/solitary or familial/multifocal).

270

271 Performance of Diagnostic Biomarker

In order to build a diagnostic biomarker of CCM activity that could improve 272 our previously published weighted biomarker formula, we tested new 273 combinations of genetic and cytokines factors. First, the previously published 274 diagnostic weighted biomarker was again confirmed to distinguish symptomatic 275 and asymptomatic patients with 14.2% sensitivity and 97.4% specificity (AUC 276 0.641 SE 0.06 CI 95% 0.512 - 0.770, p =0.03), worse than the range reported 277 previously. A similar canonical discriminant analysis approach was then 278 implemented to determine if a weighted combination of different SNPs and 279 cytokines could improve the diagnostic association with symptomatic phenotype. 280 The best weighted-biomarker included the PTPN2^{rs72872125} CC genotype and 281 GMCSF plasma levels as formulated -0,89*(GMCSF)+0,41*(*PTPN2*^{rs72872125}CC) 282 (AUC 0.663, SE 0.06 CI 95% 0.534 - 0.792, p = 0.01) with a specificity and 283 sensitivity 85.7% and 41.3%, respectively (Figure 2A). This formula outperformed 284 285 all the other possible formula (Table 1 Supplement) that had a statistically significant value. The median weighted combination value was 2.65-times 286 287 increased (p = 0.01) in symptomatic patients (median estimated value -0.36) compared with asymptomatic individuals (median estimated value -0.97) (Figure 288 289 2B). The formula performed fairly in the sub-group analysis of hemorrhagic patients (AUC 0.661, SE 0.07, CI 95% 0.517 – 0.806) but had a good accuracy 290 in familiar form of the disease (AUC 0.774, SE 0.09, CI 95% 0.595 - 0.953, p = 291 0.01) and patients with infratentorial lesions (AUC 0.804, SE 0.08, CI 95% 0.642 292 -0.966, p = 0.001) (Figure 2 C-D). Female symptomatic patients, pure epileptic 293 patients and elderly patients were not statically significant. 294

Validation Cohort with Symptomatic Event during Follow-up: Building a Prognostic Biomarker

298 We then tested if the newly weighted-diagnostic biomarker could act as a prognostic biomarker in a sub-group analysis of 42 patients that were 299 300 prospectively followed-up after initial blood collection. 4 patients experienced a symptomatic event (1 lesion growth, 2 symptomatic hemorrhage and 1 newly 301 onset epilepsy without signs of bleeding) while the others 38 stayed 302 303 asymptomatic during the next 4 years. The weighted-biomarker had a fair 304 accuracy (AUC 0.644, SE 0.078, CI 95% 0.491-0.976) in distinguishing these patients (Figure 3A). In order to verify if other combination of genetic variants and 305 306 cytokines could act as a prognostic biomarker, we first tested the 5 SNPs in the sub-group of 42 patients that were closely followed-up. We found an independent 307 statistically significant association of the FCGR2Ars1801274 GG genotype (OR 308 16.10, 95% CI 1.32 - 195.52, p = 0.029) in the age and familiar adjusted 309 multivariable analysis. This variant had an excellent accuracy (AUC 0.796, SE 310 0.12, CI 95% 0.631-0.897) in distinguishing these individuals (Figure 3B). We 311 further tested the same gene in a propensity matched subgroup. The presence 312 of the *FCGR2A*^{rs1801274} GG genotype could predict a symptomatic event with high 313 accuracy (AUC 0.875, SE 0.12, CI 95% 0.473-0.996) (Figure 3C). We also tested 314 315 if this mutation would maintain its accuracy power when comparing symptomatic patients during follow-up and individuals who have never experienced any 316 symptoms. We also found that FCGR2A^{rs1801274} GG genotype could predict a 317 symptomatic event with high accuracy (AUC 0.829, SE 0.14, CI 95% 0.519 -318 319 0.956) (Figure 3D).

320

321 In Silico Structural Analysis of Transcript FCGR2A^{rs1801274}

In silico structural analysis prediction reveals that the *FCGR2A*^{rs1801274} leads to a substitution of a histidine for an arginine at position 131 (Figure 3E). The structural alignment predicts that the variation c.500A>G (p.His131Arg) occurred in domain that appears to be conserved mainly in higher primates, within 30% of the species sharing this site (Figure 3F).

327

328 VDR variants relates to Precocity of symptoms

We tested if any of the *VDR* genetic variants could relates to a precocity of symptoms in the CCM cohort. Patients with the *VDR*^{rs731236} AA genotype tend to present their symptoms late in their life compared to those who did not have (HR 0.52, SE 0.14, CI 95% 0.299-0.909 p = 0.020) (Figure 4A). Also, individuals that harbor the *VDR*^{rs11568820} CC genotype tend to have symptoms earlier (HR 1.58, SE 0.46, CI 95% 1.092-2.282 p = 0.016 (Figure 3B).

335

336 **Discussion**

Neuroinflammation is increasingly a focus of research in symptomatic events in 337 CCM patients ²³. In the present study, we evaluated a large and phenotypically 338 well characterized CCM cohort and provided some key information about the 339 genetic influence on the behavior of this unique neurovascular disease. Here, we 340 have found an individual higher frequency of PTPN2rs72872125 CT and the 341 VDR^{rs7975232} CC genotypes in asymptomatic patients, associated with changes in 342 cytokine levels, suggesting a possible protective role. Our main new observation 343 is that the combination of a balanced formula using the PTPN2rs72872125 CC 344 genotype and serum level of GM-CSF could predict a diagnostic association with 345 symptomatic phenotype in CCM patients, while the FCGR2Ars1801274 GG 346 genotype showed the best accuracy in predicting a symptomatic event in the next 347 348 years, possibly functioning as prognostic genetic biomarker. In previous studies, we reported the association of this same variants with an aggressive phenotype 349 of cerebral cavernous malformation but in a smaller sample²². Furthermore, 350 another exciting discovery is that individuals with the VDR^{rs731236} AA and 351 VDR^{rs11568820}CC genotypes may experience an earlier onset of symptoms in the 352 CCM cohort. 353

To date, there have been few published studies on SNPs in the PTPN2 354 gene, and among them, a weak association with certain diseases or different 355 outcomes was found. However, it is important to highlight that in combination with 356 other variants they have been shown to possibly increase the susceptibility of 357 chronic inflammatory disorders, including rheumatoid arthritis, type 1 diabetes 358 and celiac disease²⁴⁻²⁸. Furthermore, there have been research findings 359 indicating the presence of epistasis between PTPN2 and VDR gene ^{29,30}. 360 Interestingly, patients who inherit the PTPN2^{rs72872125} CT genotype have high 361

All rights reserved. No reuse allowed without permission.

levels of IL-10 when compared with CC genotype (Figure 1). IL-10 is an anti-362 inflammatory molecule, with a well-established function in restraining and 363 regulating both acute and chronic inflammatory processes ³¹³². Lyne et al. (2019) 364 365 demonstrated that IL-10 is an important molecule present in diagnostic CASH biomarker and the levels were decreased in cases of individuals who had 366 experienced symptomatic CCM hemorrhage in the prior year ³³. Furthermore, the 367 CT genotype was associated with low levels of IL-18 and INF-y (Figure 1), which 368 are increased in patients with epilepsy and CCM hemorrhagic phenotype ^{34–36}. 369 370 The Canonical values derived from the best weighted formula combination with 371 GM-CSF were 2,65X higher in patients who suffered a subsequent symptomatic event (Figure 2). Like this, the a weighted combination of PTPN2rs72872125 SNP 372 and GM-CSF levels is a potential diagnostic genetic biomarker for the 373 374 symptomatic phenotype in CCM patients.

We had also provided more evidence that the FCGR2Ars1801274 GG 375 genotype could act as a prognostic biomarker of the disease. The FCGR2A gene 376 is located on chromosome 1g23 and consists of seven exons, encoding a 377 member of a family of Fcy receptors for immunoglobulin G (IgG). Through it is 378 expression in immune system cells such as macrophages, dendritic cells and 379 neutrophils, it is possible to link cellular and humoral immunity 37,38. The FCGR2A 380 381 rs1801274 variant leads to a substitution of a histidine (A allele) for an arginine (G allele) at position 131, also known as H131R. This polymorphism is capable 382 to increase the binding affinity of FCGR2A to IgG, resulting in activation of the 383 FCGR2A signaling pathway and upregulation of IgG2-dependent phagocytosis 384 ^{39,40}. The GG genotype has been associated with several autoimmune diseases, 385 such as Systemic Lupus Erythematosus, Type 1 Diabetes Mellitus, Crohn's 386 Disease and others, based on its relationship with the release and stimulation of 387 responsive inflammatory processes⁴¹. Protein structure prediction using 388 bioinformatic tools is an important approach to understand the FCGR2A variants. 389 In this study we also performed an *in-silico* analysis that demonstrated that the 390 391 H131R position is strongly conserved among higher primates, which may be related to its clinical importance. 392

Lyne et al 2019 showed an upregulation of *FCGR2B* gene in CASH transcriptomic, shedding light on the importance of Fcγ receptors in CCM disease

All rights reserved. No reuse allowed without permission.

³³. FcvRII receptors mediates the C-reactive protein (CRP)-induced changes in 395 endothelial function and inflammatory response ^{42,43}. A higher binding avidity of 396 CRP to FcyRIIa on immune cells was identified for allotype FcyRIIa-R131 397 compared to other genotypes ⁴⁴. The variant homozygous genotype (GG) was 398 able to increase the expression of ICAM-1 and E-selectin in HUVEC (Human 399 Umbilical Vein Endothelial Cells) and the levels of tPA, MCP-1, and IL-6 secreted 400 ⁴⁵. In addition, the G allele resulted in a significant defect in endothelium 401 dependent vasodilatation and reduced NO activity during endothelial cell 402 403 stimulation in patients with hypercholesterolaemia, corroborating with what has already been found in models of CCM ^{46,47}. This data could potentially impact our 404 405 comprehension of the pathophysiology of CCM disease as well as consequences with regard to the interpretation of prognostic biomarker for fallow-up of patients. 406

Growing evidence suggests that vitamin D signaling role in cavernous 407 malformation behavior ⁴⁸. Peripheral plasma vitamin D has been shown to reflect 408 the severity of CCM disease ^{49,50}. Indeed, cholecalciferol (vitamin D3), was shown 409 to decrease CCM lesion burden in a murine model of CCM, and to inhibit ROCK 410 activity, known to affect CCM development^{22,47}. The effects of vitamin D on the 411 immune system are accomplished by binding to the nuclear Vitamin D Receptor 412 (VDR). Some single nucleotide polymorphisms (SNPs) in genes involved in 413 414 vitamin D singling were reported to have association with vitamin D deficiency ⁵¹. The VDR^{rs731236} also known as Tagl, is a synonymous variant, while VDR^{rs7975232} 415 (Apal) and VDR^{rs11568820} are located in the 3' and 5'-untranslated regions of the 416 gene respectively. These SNPs do not alter the amino acid sequence in the VDR 417 protein, but they can exert influence on mRNA stability and gene transcription ⁵². 418 Especially in relation to VDR^{rs7975232}, the literature does not make clear its role in 419 relation to vitamin D levels, on the other hand we showed that patients who 420 carried the CC genotype have decreased levels of proinflammatory cytokines 421 (Figure 1). Corroborating with a possible protective role of the VDR^{rs7975232}CC 422 genotype, Jiang et al (2015) showed that A allele slightly increased the risk of 423 424 temporal lobe epilepsy in children ⁵³.

Age at the first symptom is also a fundamental information during the counselling of CCM patients. Distinguishing individuals with higher chances of precocity of symptoms that could influence their productive life is of great

importance to the CCM community. Our study provided the correlation between 428 VDR^{rs731236} AA and VDR^{rs11568820} CC genotypes to the time to first symptomatic 429 event (Figure 4). However, we could not demonstrate a straight correlation 430 between the VDR^{rs11568820} CC and VDR^{rs731236} AA genotype presence and the 431 blood concentration of any of the analyzed cytokines. The relationship between 432 VDR polymorphisms and susceptibility to autoimmunity diseases have been 433 conducted in different settings, while the results obtained so far are conflicting⁵⁴⁻ 434 ⁵⁶. We hypothesized that VDR polymorphism may affect the way proinflammatory 435 cells react to the CCM in an autoimmunity fashion leading to molecular level 436 disruption. To the best of our knowledge, this is the first study to investigate the 437 438 associations between VDR polymorphisms and cerebral cavernous malformations. 439

Previously reports demonstrated that CCM1/KRIT1 regulates vascular 440 permeability through interaction with CCM2/MGC4607 to stabilize endothelial 441 cell-cell junctions, and together they suppress RhoA activity and, thus, activation 442 of the RhoA effector ROCK⁵⁷. Mutation on these genes lead to augment of actin 443 444 stress fiber formation and increased permeability of CCMs⁵⁸⁻⁶⁰. Moreli et al (2007) have shown that BXL-628, a VDR agonist, prevented RhoA activation and 445 inhibits RhoA/Rho Kinase signaling in rat and human bladder⁶¹. Since vitamin D 446 447 is a natural agonist of VDR and animal models have suggested that fasudil and high doses of atorvastatin promotes significant inhibition of CCM lesional 448 development and hemorrhage through the RhoA/Rho Kinase rational, it is 449 reasonable to suppose that the prognostic ability of low levels of serum vitamin 450 451 D is related to these VD/VDR interactions and its genetic variants.

Our study pioneers a novel classification denoted as the "aggressive 452 453 behavior" paradigm within cerebral cavernous malformations (CCM), 454 incorporating both hemorrhage and epilepsy as integral components of its 455 symptomatic criteria. This redefined paradigm marks a transformative departure, acknowledging the critical role of epilepsy alongside hemorrhage in defining the 456 457 clinical spectrum of CCM. Unlike a diagnostic biomarker, which detects the presence of a specific medical condition, a prognostic biomarker assesses the 458 459 likelihood of progression or stability of medical conditions ⁶². These biomarkers contribute to a more precise and expedited diagnosis, as well as improved patient 460

follow-up. In summary, our study provides new pieces of evidence for possible 461 genetic biomarkers that may influence the behavior of cerebral cavernous 462 malformations. We report a novel observation that the PTPN2rs72872125 CT and 463 the VDR^{rs7975232} CC genotypes were independently associated with an 464 asymptomatic phenotype. Additionally, *PTPN2*^{rs72872125} CC genotype and serum 465 level of GM-CSF could predict a diagnostic association with symptomatic 466 phenotype in CCM patients, while the FCGR2Ars1801274 GG genotype could 467 468 predict a symptomatic event during follow-up. The study also found a correlation between VDR^{rs731236} AA and VDR^{rs11568820} CC genotype to the time to first 469 symptomatic event. Overall, this study provided valuable information on the 470 471 genetic factors that may influence the development and progression of CCM. Moreover, beyond the conventional genetic biomarker purview, our investigation 472 473 postulates a novel etiological framework. We posit an inflammatory cascade precipitating a self-non-self-interaction, instigating an autoimmune response 474 475 against CCM. This theoretical construct delineates the changes of CCM from a 476 benign anatomical variant-traditionally construed as a common disease-into 477 an aggressive lesion, now occupying the realm of a rare affliction-the aggressive behavior of CCM. This theoretical construct challenges extant 478 paradigms, accentuating the potential role of immune-mediated mechanisms in 479 the clinical trajectory of CCM, thereby offering prospects for targeted 480 immunomodulatory interventions. In essence, this study augments our 481 comprehension of genetic determinants influencing the advancement of CCM 482 while advancing a transformative hypothesis concerning the disease's underlying 483 inflammatory dynamics. These insights herald a paradigm shift in conceptualizing 484 the clinical spectrum of CCM, fostering an enriched landscape for future 485 investigative pursuits and potential therapeutic interventions aimed at modulating 486 the intricate inflammatory cascades underpinning the aggressive behavior of 487 488 CCM.

- 490 Supplemental material
- 491 Table Supplementary 1 (S1)
- 492
- 493 Correspondence

- 494 Fabrícia Lima Fontes-Dantas: ORCID https://orcid.org/0000-0002-5201-0927, e-
- 495 mail fabricia.fontesdantas@uerj.br;
- 496 Jorge Marcondes de Souza: ORCID <u>https://orcid.org/0000-0003-2412-8239</u>, e-
- 497 mail jormarcondes@gmail.com.
- 498

499 Affiliations

Laboratório de Neurociências Translacional, Programa de Pós-Graduação em 500 501 Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brasil (G.F.G., A.L.S., E.V.S., S.V.A.L.). Departamento de Neurocirurgia, 502 Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de 503 Janeiro, Rio de Janeiro RJ, Brasil (G.F.G., J.M.S.). Departamento de 504 505 Farmacologia e Psicobiologia, Instituto de Biologia Roberto Alcântara Gomes, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brasil (L.M.T, F.L.F.D). 506 Instituto Biomédico, Universidade Federal do Estado do Rio de Janeiro, Rio de 507 Janeiro, Brasil (L.M.T). Departamento de Neurologia, Hospital Universitário 508 509 Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil (S.V.A.L.). 510

511

512 Acknowledgements

The authors thank the Cavernoma Alliance Brazil Research Institute – Aliança
Cavernoma Brasil for the logistic assistance.

515

516 Sources of Funding

517 The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Brazilian National Council for 518 Scientific and Technological Development (CNPq Number 440779/2016-2), 519 Senator Romario Faria parliamentary amendment (no. 37990007 EIND), financial 520 support of Coordination for the Improvement of Higher Education Personnel 521 (CAPES Number 88887.130752/2016-00), FAPERJ E-26/210.657/2021, E-522 523 26/210.273/2018 and E-26/201.040/2021 and Chamada Pública MCTI/FINEP/CT-INFRA-PROINFRA 02/2014 - Equipamentos Multiusuários -524 Ref. nº 0097/2016. Thanks to Fundação de Amparo à Pesquisa do Estado do 525 Rio de Janeiro (FAPERJ) and Casa Hunter for the financial help to this Project. 526

All rights reserved. No reuse allowed without permission.

_	_	_
-5	2	7

528 Disclosures

529 The authors declare no competing interests

530

531 **References**

- Flemming KD, Graff-Radford J, Aakre J, Kantarci K, Lanzino G, Brown RDJ, Mielke MM, Roberts RO, Kremers W, Knopman DS, et al.
 Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging. JAMA Neurol. 2017;74:801– 805.
- Spiegler S, Rath M, Paperlein C, Felbor U. Cerebral Cavernous
 Malformations: An Update on Prevalence, Molecular Genetic Analyses, and Genetic Counselling. *Mol. Syndromol.* 2018;9:60–69.
- de Souza JM, Domingues RC, Cruz LCH, Domingues FS, Iasbeck T,
 Gasparetto EL. Susceptibility-Weighted Imaging for the Evaluation of
 Patients with Familial Cerebral Cavernous Malformations: A Comparison
 with T2-Weighted Fast Spin-Echo and Gradient-Echo Sequences. Am. J.
 Neuroradiol. [Internet]. 2008;29:154–158. Available from:
 http://www.ajnr.org/lookup/doi/10.3174/ajnr.A0748
- Salman RA-S, Hall JM, Horne MA, Moultrie F, Josephson CB,
 Bhattacharya JJ, Counsell CE, Murray GD, Papanastassiou V, Ritchie V,
 et al. Untreated clinical course of cerebral cavernous malformations: a
 prospective, population-based cohort study. *Lancet Neurol.* [Internet].
 2012;11:217–224. Available from: http://dx.doi.org/10.1016/S1474-
- 551 4422(12)70004-2
- Ironside JW. Pathology of tumours of the nervous system. (5th ed.). D. S.
 Russell and L. J. Rubinstein. Edward Arnold, London, 1989. No. of pages:
 1012. Price: £110.00. ISBN: 07131 4549 8. *J. Pathol.* [Internet].
- 555 1989;158:359–359. Available from:
- 556 https://doi.org/10.1002/path.1711580413
- 6. Weinsheimer S, Nelson J, Abla AA, Ko NU, Tsang C, Okoye O,
 Zabramski JM, Akers A, Zafar A, Mabray MC, et al. Intracranial
 Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral
 Cavernous Malformation. J. Am. Heart Assoc. [Internet].
- 561 2023;12:e027572. Available from:
- 562 https://www.ahajournals.org/doi/10.1161/JAHA.122.027572
- 563 7. Dashti SR, Hoffer A, Hu YC, Selman WR. Molecular genetics of familial
 564 cerebral cavernous malformations. *Neurosurg. Focus.* 2006;21:e2.
- 5658.Gross BA, Lin N, Du R, Day AL. The natural history of intracranial566cavernous malformations. *Neurosurg. Focus.* 2011;30:E24.
- 567 9. Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of
 568 cavernous angiomas. *Lancet Neurol.* [Internet]. 2007;6:237–244.
 569 Available from:
- 570 https://linkinghub.elsevier.com/retrieve/pii/S1474442207700534

571 572 573 574	10.	Gault J, Sain S, Hu L-J, Awad IA. SPECTRUM OF GENOTYPE AND CLINICAL MANIFESTATIONS IN CEREBRAL CAVERNOUS MALFORMATIONS. <i>Neurosurgery</i> [Internet]. 2006;59:1278–1285. Available from: https://journals.lww.com/00006123-200612000-00015
575 576 577 578 579	11.	Snellings DA, Hong CC, Ren AA, Lopez-Ramirez MA, Girard R, Srinath A, Marchuk DA, Ginsberg MH, Awad IA, Kahn ML. Cerebral Cavernous Malformation: From Mechanism to Therapy. <i>Circ. Res.</i> [Internet]. 2021;129:195–215. Available from: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318174
580 581 582 583 584 585	12.	Koskimäki J, Polster SP, Li Y, Romanos S, Srinath A, Zhang D, Carrión- Penagos J, Lightle R, Moore T, Lyne SB, et al. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. <i>GeroScience</i> [Internet]. 2020;42:1351–1363. Available from: https://link.springer.com/10.1007/s11357-020-00201-4
586 587 588	13.	Shenkar R, Shi C, Check IJ, Lipton HL, Awad IA. Concepts and hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations. <i>Neurosurgery</i> . 2007;61:693.
589 590 591	14.	Shi C, Shenkar R, Du H, Duckworth E, Raja H, Batjer HH, Awad IA. Immune response in human cerebral cavernous malformations. <i>Stroke</i> . 2009;40:1659–1665.
592 593 594 595	15.	Shi C, Shenkar R, Kinloch A, Henderson SG, Shaaya M, Chong AS, Clark MR, Awad IA. Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. <i>J. Neuroimmunol.</i> 2014;272:67–75.
596 597 598 599	16.	Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. <i>Am. J.</i> <i>Pathol.</i> 2004;165:1509–1518.
600 601 602 603	17.	Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M, Ferrarini L, Orsenigo F, Papa E, Boulday G, et al. EndMT contributes to the onset and progression of cerebral cavernous malformations. <i>Nature</i> . 2013;498:492–496.
604 605 606 607 608 609 610	18.	Fontes-Dantas FL, da Fontoura Galvão G, Veloso da Silva E, Alves-Leon S, Cecília da Silva Rêgo C, Garcia DG, Marques SA, Blanco Martinez AM, Reis da Silva M, Marcondes de Souza J. Novel CCM1 (KRIT1) Mutation Detection in Brazilian Familial Cerebral Cavernous Malformation: Different Genetic Variants in Inflammation, Oxidative Stress, and Drug Metabolism Genes Affect Disease Aggressiveness. <i>World Neurosurg.</i> 2020;138:535-540.e8.
611 612 613 614 615	19.	Choquet H, Pawlikowska L, Nelson J, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H. Polymorphisms in Inflammatory and Immune Response Genes Associated with Cerebral Cavernous Malformation Type 1 Severity. <i>Cerebrovasc. Dis.</i> [Internet]. 2014;38:433– 440. Available from: https://www.karger.com/Article/FullText/369200
616 617	20.	Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, Girard R, Zeineddine HA, Lightle R, Moore T, et al. Endothelial TLR4 and the

	microbiome drive cerebral cavernous malformations. <i>Nature</i> . 2017;545:305–310.
21.	Perrelli A, Retta SF. Polymorphisms in genes related to oxidative stress and inflammation: Emerging links with the pathogenesis and severity of Cerebral Cavernous Malformation disease. <i>Free Radic. Biol. Med.</i> [Internet]. 2021;172:403–417. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0891584921003865
22.	da Fontoura Galváo G, Fontes-Dantas FL, da Silva EV, Alves-Leon SV, de Souza JM. Association of Variants in FCGR2A, PTPN2, and GM-CSF with Cerebral Cavernous Malformation: Potential Biomarkers for a Symptomatic Disease. <i>Curr. Neurovasc. Res.</i> [Internet]. 2021;18:172–180. Available from: https://www.eurekaselect.com/193838/article
23.	Lai CC, Nelsen B, Frias-Anaya E, Gallego-Gutierrez H, Orecchioni M, Herrera V, Ortiz E, Sun H, Mesarwi OA, Ley K, et al. Neuroinflammation Plays a Critical Role in Cerebral Cavernous Malformation Disease. <i>Circ.</i> <i>Res.</i> [Internet]. 2022;131:909–925. Available from: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.122.321129
24.	McCole DF. Regulation of epithelial barrier function by the inflammatory bowel disease candidate gene, PTPN2. <i>Ann. N. Y. Acad. Sci.</i> [Internet]. 2012;1257:108–114. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2012.06522.x
25.	Bottini N, Peterson EJ. Tyrosine Phosphatase PTPN22: Multifunctional Regulator of Immune Signaling, Development, and Disease. <i>Annu. Rev.</i> <i>Immunol.</i> [Internet]. 2014;32:83–119. Available from: https://www.annualreviews.org/doi/10.1146/annurev-immunol-032713- 120249
26.	Santin I, Moore F, Colli ML, Gurzov EN, Marselli L, Marchetti P, Eizirik DL. PTPN2, a Candidate Gene for Type 1 Diabetes, Modulates Pancreatic β -Cell Apoptosis via Regulation of the BH3-Only Protein Bim. <i>Diabetes</i> [Internet]. 2011;60:3279–3288. Available from: https://diabetesjournals.org/diabetes/article/60/12/3279/14490/PTPN2-a-Candidate-Gene-for-Type-1-Diabetes
27.	Hsieh W-C, Svensson MN, Zoccheddu M, Tremblay ML, Sakaguchi S,

- kaguchi S, Stanford SM, Bottini N. PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis. JCI Insight [Internet]. 2020;5. Available from: https://insight.jci.org/articles/view/141868
- Shaw AM, Qasem A, Naser SA. Modulation of PTPN2/22 Function by 28. Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn's Disease and Rheumatoid Arthritis. Int. J. Mol. Sci. [Internet]. 2021;22:8883. Available from: https://www.mdpi.com/1422-0067/22/16/8883
- Ramagopalan S V, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, 29. Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton S-M, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res. [Internet]. 2010;20:1352–1360. Available from: http://genome.cshlp.org/lookup/doi/10.1101/gr.107920.110

665 666 667 668 669 670	30.	Ellis JA, Scurrah KJ, Li YR, Ponsonby A-L, Chavez RA, Pezic A, Dwyer T, Akikusa JD, Allen RC, Becker ML, et al. Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis. <i>J. Steroid Biochem. Mol. Biol.</i> [Internet]. 2015;145:113–120. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960076014002477
671 672 673 674	31.	Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. <i>Proc. Natl.</i> <i>Acad. Sci.</i> [Internet]. 2005;102:8686–8691. Available from: https://pnas.org/doi/full/10.1073/pnas.0500419102
675 676 677 678	32.	Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. <i>Cytokine Growth Factor Rev.</i> [Internet]. 2010;21:331–344. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1359610110000651
679 680 681 682	33.	Lyne SB, Girard R, Koskimäki J, Zeineddine HA, Zhang D, Cao Y, Li Y, Stadnik A, Moore T, Lightle R, et al. Biomarkers of cavernous angioma with symptomatic hemorrhage. <i>JCI Insight</i> [Internet]. 2019;4. Available from: https://insight.jci.org/articles/view/128577
683 684 685 686 687	34.	Mochol M, Taubøll E, Aukrust P, Ueland T, Andreassen OA, Svalheim S. Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation. <i>Seizure</i> [Internet]. 2020;80:221–225. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1059131120301473
688 689 690 691	35.	Gao F, Gao Y, Zhang S -j., Zhe X, Meng F-L, Qian H, Zhang B, Li Y-J. Alteration of plasma cytokines in patients with active epilepsy. <i>Acta</i> <i>Neurol. Scand.</i> [Internet]. 2017;135:663–669. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ane.12665
692 693 694 695 696 697	36.	Girard R, Zeineddine HA, Fam MD, Mayampurath A, Cao Y, Shi C, Shenkar R, Polster SP, Jesselson M, Duggan R, et al. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. <i>Transl. Stroke Res.</i> [Internet]. 2018;9:34–43. Available from: http://link.springer.com/10.1007/s12975- 017-0561-3
698 699 700	37.	Zhang C, Wang W, Zhang H, Wei L, Guo S. Association of FCGR2A rs1801274 polymorphism with susceptibility to autoimmune diseases: A meta-analysis. <i>Oncotarget</i> . 2016;7:39436–39443.
701 702 703 704	38.	Duan J, Lou J, Zhang Q, Ke J, Qi Y, Shen N, Zhu B, Zhong R, Wang Z, Liu L, et al. A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis. <i>PLoS One</i> . 2014;9:e103329.
705 706 707 708 709	39.	Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. <i>J. Immunol.</i> [Internet]. 1991;147:1338–1343. Available from: https://journals.aaj.org/jimmunol/article/147/4/1338/24700/A-single-amino-
710		acid-in-the-second-lg-like-domain
711	40.	Shrestha S, Wiener HW, Olson AK, Edberg JC, Bowles NE, Patel H,

712 713 714 715		Portman MA. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. <i>J. Allergy Clin. Immunol.</i> [Internet]. 2011;128:677-680.e1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0091674911006646
716 717 718	41.	Hayat S, Babu G, Das A, Howlader ZH, Mahmud I, Islam Z. Fc-gamma IIIa-V158F receptor polymorphism contributes to the severity of Guillain- Barré syndrome. <i>Ann. Clin. Transl. Neurol.</i> 2020;7:1040–1049.
719 720 721 722 723	42.	Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L, Shohet R V, Black S, Salmon JE, Samols D, et al. FcγRIIB Mediates C-Reactive Protein Inhibition of Endothelial NO Synthase. <i>Circ.</i> <i>Res.</i> [Internet]. 2005;97:1124–1131. Available from: https://www.ahajournals.org/doi/10.1161/01.RES.0000194323.77203.fe
724 725 726 727 728	43.	RYU J, LEE C, SHIN J, PARK C, KIM J, PARK S, HAN K. FcγRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. <i>Cardiovasc. Res.</i> [Internet]. 2007;75:555–565. Available from: https://doi.org/10.1016/j.cardiores.2007.04.027
729 730 731 732	44.	Stein M-P, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW. C-reactive protein binding to FcγRIIa on human monocytes and neutrophils is allele-specific. <i>J. Clin. Invest.</i> [Internet]. 2000;105:369– 376. Available from: http://www.jci.org/articles/view/7817
733 734 735 736 737	45.	Raaz-Schrauder D, Ekici AB, Klinghammer L, Stumpf C, Achenbach S, Herrmann M, Reis A, Garlichs CD. The proinflammatory effect of C- reactive protein on human endothelial cells depends on the FcyRIIa genotype. <i>Thromb. Res.</i> [Internet]. 2014;133:426–432. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049384813006166
738 739 740 741 742	46.	Schneider MP, Leusen JHW, Herrmann M, Garlichs CD, Amann K, John S, Schmieder RE. The Fcy receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia. <i>Atherosclerosis</i> [Internet]. 2011;218:411–415. Available from:
743 744 745 746 747 748	47.	Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J, Walker AE, Goitre L, Delle Monache S, Retta SF, et al. Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation. <i>Circulation</i> [Internet]. 2015;131:289–299. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.114.010403
749 750	48.	Awad IA, Polster SP. Cavernous angiomas: deconstructing a neurosurgical disease. <i>J. Neurosurg.</i> 2019;131:1–13.
751 752 753 754	49.	Girard R, Khanna O, Shenkar R, Zhang L, Wu M, Jesselson M, Zeineddine HA, Gangal A, Fam MD, Gibson CC, et al. Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. <i>Biomark. Med.</i> 2016;10:255–264.
755 756 757 758	50.	Akers A, Al-Shahi Salman R, A. Awad I, Dahlem K, Flemming K, Hart B, Kim H, Jusue-Torres I, Kondziolka D, Lee C, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by

759 760 761		the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. <i>Neurosurgery</i> [Internet]. 2017;80:665–680. Available from: https://journals.lww.com/00006123-201705000-00012
762 763 764 765 766	51.	Krasniqi E, Boshnjaku A, Wagner K-H, Wessner B. Association between Polymorphisms in Vitamin D Pathway-Related Genes, Vitamin D Status, Muscle Mass and Function: A Systematic Review. <i>Nutrients</i> [Internet]. 2021;13:3109. Available from: https://www.mdpi.com/2072- 6643/13/9/3109
767 768 769 770	52.	Uitterlinden AG, Fang Y, van Meurs JBJ, Pols HAP, van Leeuwen JPTM. Genetics and biology of vitamin D receptor polymorphisms. <i>Gene</i> [Internet]. 2004;338:143–156. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0378111904003075
771 772 773 774 775	53.	Jiang P, Zhu W-Y, He X, Tang M-M, Dang R-L, Li H-D, Xue Y, Zhang L- H, Wu Y-Q, Cao L-J. Association between Vitamin D Receptor Gene Polymorphisms with Childhood Temporal Lobe Epilepsy. <i>Int. J. Environ.</i> <i>Res. Public Health</i> [Internet]. 2015;12:13913–13922. Available from: http://www.mdpi.com/1660-4601/12/11/13913
776 777 778 779	54.	Fouad H, Yahia S, Elsaid A, Hammad A, Wahba Y, El-Gilany A-H, Abdel- Aziz A-AF. Oxidative stress and vitamin D receptor Bsml gene polymorphism in Egyptian children with systemic lupus erythematosus: a single center study. <i>Lupus</i> . 2019;28:771–777.
780 781 782 783	55.	Ghaly MS, Badra DI, Dessouki O, Elmaraghy NN, Hassan R. Vitamin D receptor Fok1 & Bsm 1 Gene Polymorphisms in Systemic Lupus Erythematosus and Osteoarthritis: Autoimmune Inflammatory versus Degenerative Model. <i>Egypt. J. Immunol.</i> 2017;24:151–164.
784 785 786	56.	Tizaoui K, Hamzaoui K. Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta- analysis of case-control studies. <i>Immunobiology</i> . 2015;220:807–816.
787 788 789	57.	Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. <i>J. Exp. Med.</i> 2010;207:881–896.
790 791 792 793	58.	Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. <i>J. Biol. Chem.</i> 2010;285:11760–11764.
794 795 796 797	59.	Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, Mayo AH, Drakos SG, Jones CA, Zhu W, et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. <i>Nat. Med.</i> 2009;15:177–184.
798 799 800 801	60.	Crose LES, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. <i>J. Biol. Chem.</i> 2009;284:13301–13305.
802 803 804 805	61.	Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, Crescioli C, Donati S, Fibbi B, Colli E, et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human

All rights reserved.	No reuse allowed without permission.	

806		bladder. <i>Prostate</i> . 2007;67:234–247.
807 808 809 810 811	62.	Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. <i>Clin. Pharmacol.</i> <i>Ther.</i> [Internet]. 2015;98:34–46. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cpt.136
812 813 814 815 816	63.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Lancet</i> [Internet]. 2007;370:1453–1457. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067360761602X
817 818 819 820	64.	Fontes FL, de Araújo LF, Coutinho LG, Leib SL, Agnez-Lima LF. Genetic polymorphisms associated with the inflammatory response in bacterial meningitis. <i>BMC Med. Genet.</i> [Internet]. 2015;16:1–12. Available from: http://dx.doi.org/10.1186/s12881-015-0218-6
821 822 823 824 825 826	65.	Chehuen Bicalho V, da Fontoura Galvão G, Lima Fontes-Dantas F, Paulo da Costa Gonçalves J, Dutra de Araujo A, Carolina França L, Emílio Corrêa Leite P, Campolina Vidal D, Castro Filho R, Vieira Alves-Leon S, et al. Asymptomatic cerebral cavernous angiomas associated with plasma marker signature. <i>J. Clin. Neurosci.</i> [Internet]. 2021;89:258–263. Available from:
827 828 829 830 831 832	66.	da Fontoura Galvão G, da Silva EV, Trefilio LM, Alves-Leon SV, Fontes- Dantas FL, de Souza JM. Comprehensive CCM3 Mutational Analysis in Two Patients with Syndromic Cerebral Cavernous Malformation. <i>Transl.</i> <i>Stroke Res.</i> [Internet]. 2023;Available from: https://link.springer.com/10.1007/s12975-023-01131-x
833 834 835 836	67.	Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera?A visualization system for exploratory research and analysis. <i>J. Comput. Chem.</i> [Internet]. 2004;25:1605–1612. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jcc.20084
837 838 839 840	68.	Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. <i>Nucleic Acids Res.</i> [Internet]. 2004;32:1792–1797. Available from: https://academic.oup.com/nar/article- lookup/doi/10.1093/nar/gkh340
841		
842		
843		
844 945	Logo	
846	геде	nu riguico
847	Figur	e 1: Association of PTPN2 and VDR to a Symptomatic Phenotype, Linkage
848	Dised	uilibrium Map and Plasmatic Cytokine Expression. (A) Haplotype map
849	show	ing the 3 SNPs analyzed and the range of R ² value, suggesting that
850	VDR ^r	^{s7975232} and VDR ^{rs731236} are in linkage disequilibrium (D'>0.99), while the

other combinations segregate independently VDR^{rs11568820} and VDR^{rs731236} 851 (D'>0.04), VDR^{rs11568820} and VDR rs7975232 (D'>0.317). (B) ROC analysis 852 evidencing the performance of *PTPN2*^{rs72872125} CT genotype (AUC 0.420) and (C) 853 *VDR*^{rs7975232} CC (AUC 0.439) to distinguish symptomatic patients. (D) Plasmatic 854 cytokine expression between PTPN2rs72872125 groups showing the PTPN2rs72872125 855 CT genotype have higher plasma level of IL-10 (p = 0.0146), (E) low levels of IL-856 18 (p = 0.0450) and (F) low levels of IFN- γ (p = 0.0310) (Figure 1F), while 857 individuals with at least one VDR^{rs7975232} C allele had (G) low plasma levels of IL-858 27 (p = 0.0055) and (H) low plasma levels of IL-23 (p = 0.0034). 859

860

Figure 2: Performance of Diagnostic Biomarker. (A) ROC curve of the best 861 weighted-biomarker included PTPN2rs72872125 CC genotype and GMCSF plasma 862 levels as formulated -0,89*(GMCSF)+0,41*(PTPN2rs72872125CC) (AUC 0.663. SE 863 0.06 CI 95% 0.534 – 0.792, p = 0.01) with a specificity and sensitivity 85.7% and 864 865 41.3%, respectively. (B) The median weighted combination value was 2.65-times increased (p = 0.01) in symptomatic patients (median estimated value -0.36) 866 compared with asymptomatic individuals (median estimated value -0.97). Sub-867 group analysis demonstrating that the formula performed fairly in the sub-group 868 analysis of (C) symptomatic bleeding patients (AUC 0.661, SE 0.07, CI 95% 869 0.517 – 0.806) but had a good accuracy in (D) familiar form of the disease (AUC 870 0.774, SE 0.09, CI 95% 0.595 - 0.953, p = 0.01) and (E) patients with 871 infratentorial lesions (AUC 0.804, SE 0.08, CI 95% 0.642 - 0.966, p = 0.001). 872

873

Figure 3: Performance of Prognostic Biomarker and In Silico Structural Analysis 874 of Transcript FCGR2A^{rs180127}. (A) The weighted-biomarker had a fair accuracy 875 876 (AUC 0.644, SE 0.078, CI 95% 0.491-0.976) as prognostic biomarker while FCGR2A^{rs1801274} GG (B) genotype had an excellent accuracy (AUC 0.796, SE 877 0.12, CI 95% 0.631-0.897) in distinguishing these patients. (C) ROC curve 878 evidencing the performance of the FCGR2Ars1801274 GG genotype after PSM 879 analysis (AUC 0.875) and (D) in a sub-group of pure asymptomatic patients (AUC 880 0.829). (E) In silico structural analysis prediction reveals that the FCGR2A^{rs1801274} 881 leads to a substitution of a histidine for an arginine at position 131 leading to a 882 predicted conformational structure slightly different than the wild-type. (F) 883

884 Structural alignment predicts that the mutation c.500A>G (p.His131Arg) occurred 885 in domain conserved in higher primates, within 30% of the species sharing this site.

886

Figure 4: *Kaplan-Meier curve demonstrating that VDR variants are related to Precocity of symptoms.* (A) $VDR^{rs731236}$ AA genotype tend to have symptoms later in life compared to those who did not have (HR 0.52, p = 0.020). (B) Individuals that harbor the $VDR^{rs11568820}$ CC genotype tend to have symptoms earlier (HR 1.58, p = 0.016).

TABLES 893

894

Table 1: Studied SNPs and their basic characteristics and female sex adjusted 895 896 multivariable analysis.

Gene	SNP ID	Alternative	Chr/Location	Nucleotide	Aminoacid	MAF
		Name		Change	Change	ALFA
PTPN2	rs72872125		18/intron	C>T		0.11
VDR	rs7975232	Apa1	12/intron	C>A		0.55
	rs731236	Taq1	12/exon	A>G	lle > lle	0.38
	rs11568820		12/intron	C>T		0.28
FCGR2A	rs1801274		1/exon	A>G	His > Arg	0.51

897

Chr - chromosome; MAF - minimal allele frequency 898

900 Table 2: Summary of the Demographic and Clinical Characteristics

Characteristics	N (%)	Multifocal/Familiar	Age (years), mean	Sex: Female, n
Asymptomatic	33 (32%)	13	46.3	22
Symptomatic	70 (67%)	31	45.3	43
Hemorrhage	48 (46%)	20	41.6	33
Epilepsy	22 (21%)	11	53.7	10
Total	103	44	45.6	65

901

902 N - absolute number

903

904

medRxiv preprint doi: https://doi.org/10.1101/2023.12.30.23300669; this version posted January 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

proprint (million had not continue by poor rottom) is the addition and of, this had granted mean art a noonlos to alog	July the pr
perpetuity.	
All rights reserved. No reuse allowed without permission.	

Gene	e SNP ID	Allele	Symptomatic	Asymptomatic	OR (95% CI)	Р
PTPN	l2 rs72872125	CC	59	22	2.83 (1.04-7.67)	0.04
		СТ	8	9	0.34 (0.11-0.99)	
VDR	rs7975232	CC	1	5	0.06 (0.006-0.6120)	0.017
		AC	20	5	2.33 (0,782-6.949)	0.128
		AA	47	22	1.00 (0.403-2.500)	0.993
	rs731236	GG	12	3	2.16 (0.525 - 8.942)	0.779
		AG	21	16	1.06 (0.408-2.789)	0.893
		AA	30	14	0.89 (0.349-2.220)	0.808
	rs11568820	ТТ	15	5	1.36 (0.434 - 4.298)	0.893
		СТ	25	14	0.73 (0.298-1.817)	0.507
		CC	30	12	0.71 (0.288-1.783)	0.474
FCGR	2A rs1801274	GG	19	8	1.14 (0.438 - 3.007)	0.962
		AG	36	14	0.71 (0.288-1.771)	0.469
		AA	14	11	0.71 (0.288-1.775)	0.471

Table 3: Association between SNPs and Different Phenotypes in the age, 906 familiar and female sex adjusted multivariable analysis 907

908

OR: Odds Ratio; CI: Confidential Interval. Data analyzed through binary logistic 909

P < 0.05 are highlighted in bold regression. 910

911

Figure 1



Figure 2 933







951

952



Α

В



- 955
- 956

